Horizon completes acquisition of Raptor

Horizon Pharma has completed the acquisition of Raptor Pharmaceutical.

Horizon Chief Executive Office (CEO) Timothy P. Walbert has said that the Raptor buy is along Horizon’s long term strategy, as the company aims to focus more on rare diseases.

“More than half of our medicines are used to treat patients with rare diseases,” said Walbert, who is also the chairman and president of the company

“The added infrastructure in Europe and other key international markets will further benefit the access to both our current and newly acquired medicines as well as position us for the potential introduction of ACTIMMUNE for Friedreich’s ataxia in Europe in future years if the results of the Phase 3 trial are positive,” he added.

Horizon Pharma has completed its acquisition of Raptor through the merger of Misneach Corporation without a vote of Raptor’s stockholders. As a result of the merger, Raptor became an indirect wholly owned subsidiary of Horizon Pharma.

To remind, Horizon Pharma announced two weeks ago that, with its wholly owned subsidiaries, Horizon Pharma, Inc. and Horizon Pharma USA, Inc., intended to offer $300 million aggregate principal amount of senior notes due 2024, and to borrow $375 million in order to complete the Raptor purchase.

 

 

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s